Collegium turns to GAAP net loss of $15.1 million in Q2 FY26; revenue rises 6% to $199.9 million

Reuters2026/08/06 11:35

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Collegium Pharmaceutical posted Q2 GAAP net loss of $15.1 million, turning from profit; GAAP loss per share was $0.46.
Product revenues, net rose 6% year over year to $199.9 million; GAAP operating expenses climbed 45% to $106.6 million.
Non-GAAP adjusted EBITDA increased 8% to $113.8 million; non-GAAP adjusted net income rose to $75.4 million, or $1.92 per share.
JORNAY PM product revenue, net jumped 41% to $46.1 million; AZSTARYS added $12.9 million from May 12 through quarter-end after the acquisition closed.
2026 guidance cut for product revenues, net to $825 million-$855 million; adjusted EBITDA trimmed to $445 million-$470 million on lower authorized-generic Nucynta pricing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Collegium Pharmaceutical Inc. published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Collegium turns to GAAP net loss of $15.1 million in Q2 FY26; revenue rises 6% to $199.9 million

You may also like

Crypto prices